N

NewAmsterdam Pharma Company NV
NASDAQ:NAMS

Watchlist Manager
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
Watchlist
Price: 32.69 USD -4.89%
Market Cap: 3.7B USD

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of NAMS.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NAMS Intrinsic Value
Not Available
N
Base Case Scenario
Compare NAMS to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about NAMS?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
NewAmsterdam Pharma Company NV

Balance Sheet Decomposition
NewAmsterdam Pharma Company NV

Current Assets 389.3m
Cash & Short-Term Investments 383.5m
Other Current Assets 5.8m
Non-Current Assets 81.8m
PP&E 112k
Intangibles 81.6m
Other Non-Current Assets 93k
Current Liabilities 38.3m
Accounts Payable 20.9m
Other Current Liabilities 17.5m
Non-Current Liabilities 10.5m
Long-Term Debt 23k
Other Non-Current Liabilities 10.5m
Efficiency

Free Cash Flow Analysis
NewAmsterdam Pharma Company NV

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
NewAmsterdam Pharma Company NV

Revenue
107.1m EUR
Operating Expenses
-254m EUR
Operating Income
-146.9m EUR
Other Expenses
-11m EUR
Net Income
-157.9m EUR
Fundamental Scores

NAMS Profitability Score
Profitability Due Diligence

NewAmsterdam Pharma Company NV's profitability score is 11/100. The higher the profitability score, the more profitable the company is.

Low 3Y Average Gross Margin
Declining Net Margin
Low Gross Margin
Declining Operating Margin
11/100
Profitability
Score

NewAmsterdam Pharma Company NV's profitability score is 11/100. The higher the profitability score, the more profitable the company is.

NAMS Solvency Score
Solvency Due Diligence

NewAmsterdam Pharma Company NV's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

NewAmsterdam Pharma Company NV's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NAMS Price Targets Summary
NewAmsterdam Pharma Company NV

Wall Street analysts forecast NAMS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NAMS is 49.74 USD with a low forecast of 37.37 USD and a high forecast of 63 USD.

Lowest
Price Target
37.37 USD
14% Upside
Average
Price Target
49.74 USD
52% Upside
Highest
Price Target
63 USD
93% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

NewAmsterdam Pharma Company NV
does not pay dividends
Shareholder Yield

Current shareholder yield for NAMS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

NAMS Insider Trading
Buy and sell transactions by insiders